Article

A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers

2025-11-07

Abstract excerpt

<h4>SUMMARY</h4> The tumor suppressor TP53 gene (p53) is mutated in most human malignancies; however, existing treatment options are largely ineffective, lack selectivity, and cause toxic side effects. To address these clinical problems, we developed a sequential triple-drug strategy for p53 mutant cancer cells. Here we show that a combination of a thymidine analogue (TAS102) plus PARP inhibitor (PARPi) promotes...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 330b67e7-9b88-5e8f-b73e-5c799dd5d570
DOI: 10.1101/2025.11.06.687028

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant CancersDOI 10.1101/2025.11.06.687028Read

A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancersSemantic proximity Read

P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathwaySemantic proximity Read

Therapeutic Targeting of DNA Damage Response Pathways in TP53 - and ATM -Mutated TumorsSemantic proximity Read

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.Semantic proximity Read

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesSemantic proximity Read

Preferential killing of p53-deficient cancer cells by reversineSemantic proximity Read

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatmentSemantic proximity Read

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing FerroptosisSemantic proximity Read

A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53Semantic proximity Read

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53.Semantic proximity Read

Novel Combinatorial Therapeutic Strategy to Overcome Gain-of-Function p53 MutationsSemantic proximity Read

Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope.Semantic proximity Read